Alnylam grants InterfeRx license to Sylentis

Alnylam Pharmaceuticals (NASDAQ:ALNY) has granted Spain’s Sylentis a non-exclusive option for a new target-specific InterfeRx license that would enable Sylentis to develop and commercialize a synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma. If the option is exercised, Alnylam would receive upfront and milestone payments, as well as royalties on sales [...]

Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]